Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors (The HARMONIC Study)

Next Previous
X
Search
Trial Profile

Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors (The HARMONIC Study)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dimesna (Primary) ; Carboplatin; Pemetrexed
  • Indications Adenocarcinoma; Bronchiolo-alveolar adenocarcinoma; Carcinoma; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms HARMONIC; Harmonica
  • Sponsors Lantern Pharma

    • Most Recent Events

    • 24 Apr 2024 According to a Lantern Pharma media release, company will present a webinar on Wednesday on April 24, 2024-1:00pm ET to discuss successes and future of the Harmonic Phase 2 clinical trial.
    • 22 Apr 2024 According to a Lantern Pharma media release, the company has received regulatory approval to expand this trial, in non-small cell lung cancer in never-smokers in both Japan and Taiwan.
    • 08 Nov 2023 According to a Lantern Pharma media release, progressed this clinical trial towards enrollment in East Asian countries where 30-35+% of all lung cancer cases occur in never-smokers with NSCLC; continued expansion of additional clinical trial sites in the US and increased focus on recruitment activity with advocacy groups.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top